eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
4/2019
vol. 11
 
Share:
Share:
more
 
 
abstract:
Case report

A rare manifestation of chronic lymphocytic leukaemia – leukaemia cutis treated with ibrutinib

Małgorzata Osmola
1
,
Beata Gierej
2
,
Anna Waszczuk-Gajda
1
,
Agata Dominika Kłosowicz
3
,
Marta Hałaburda-Rola
4
,
Wiesław Wiktor Jędrzejczak
1
,
Grzegorz Władysław Basak
1
,
Bogna Ziarkiewicz-Wróblewska
2

1.
Department of Haematology, Oncology, and Internal Diseases, University Clinical Centre, Medical University of Warsaw
2.
Department of Pathomorphology, Medical University of Warsaw
3.
Department of Dermatology, University Hospital, Medical University of Cracow
4.
Department of Radiology, University Clinical Centre, Medical University of Warsaw
Medycyna Paliatywna 2019; 11(4): 180–183
Online publish date: 2020/03/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Skin infiltration by leukaemia (leukaemia cutis – LC) in chronic lymphocytic leukaemia (CLL) occurs in less than 5% of affected patients. It is significantly less common than skin cancers complicating the course of CLL, with an incidence of up to 20%, and non-specific skin lesions. Therefore, it is crucial to perform additional diagnostic tests to establish the aetiology of skin lesions in CLL patients.

In this report, we present a case of a 60-year-old woman with CLL, in whom diffuse skin lesions were observed seven years after diagnosis, histologically confirmed as CLL infiltrates, and who responded well to treatment with ibrutinib.
keywords:

chronic lymphocytic leukaemia, leukaemia cutis, ibrutinib

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe